EIF2A and gastric cancer: To evaluate whether the activation of ISR is able to induce cisplatin resistance, we treated three human gastric cancer cell lines (AGS, AZ521, NUGC-3) with the eIF2α phosphatase inhibitor salubrinal to maintain the phosphorylation status of eIF2α and to increase ATF4 protein expression levels (Figure 1A).